The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy.
The feasibility of employing adjuvant topical mechlorethamine after electron beam therapy in the treatment of patients with mycosis fungoides is demonstrated. Patients treated with a planned adjuvant topical mechlorethamine schedule had a median disease-free interval of 25 months compared to 17 months for the group treated with electron beam therapy alone. Projected relapse-free survivals are slightly better in the adjuvant group--37% versus 29%. Patients receiving adjuvant topical mechlorethamine after the electron beam were observed to have a low incidence of contact allergy to the medication. The topical medication can be continued if a contact allergy develops by using a planned desensitization program. We currently treat all mycosis fungoides patients with electron beam therapy, randomizing half to receive adjuvant topical mechlorethamine.
D000287:Administration, Topical; D003877:Dermatitis, Contact / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000628:therapy*; D011882:Radiotherapy, High-Energy; D012075:Remission, Spontaneous; D012878:Skin Neoplasms / Q000628:therapy*; D013997:Time Factors
D008466:Mechlorethamine